Delivery Order SPE2DB25D3404-SPE2DB25FUPRA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count package) under a firm fixed price contract. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Ibrance 75 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,123.96. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,247.92 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count packaging) under a firm fixed price contract. The contract was competitively awarded without a set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Ibrance 125 mg capsules (21-count packages). The contract, valued at $16,236.16, was awarded on June 20, 2025, with a completion date of July 14, 2025, under a firm fixed-price delivery order arrangement. This is a non-set-aside award, indicating it was competitively procured. The work will be...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count packaging) with a firm fixed price arrangement. The contract, which was competitively awarded without a set-aside designation, carries an ultimate completion date of September 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUPRADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count package) valued at $8,118.08 under a firm fixed price contract type. The award, issued on August 6, 2025, with an ultimate completion date of August 27, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same city. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp supplies an extensive portfolio of pharmaceutical products and medical commodities to support military and veteran healthcare systems. Ibrance (palbociclib) is a targeted cancer therapy used primarily in breast cancer treatment, reflecting the company's role in delivering specialized medications across multiple therapeutic domains. The DLA Troop Support Medical IDC enables AmerisourceBergen to supply brand-name and generic drugs, vaccines, medical devices, and other healthcare commodities to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. This delivery order represents one of numerous pharmaceutical supplies the contractor furnishes through its existing federal contract relationships with the DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 8/6/25 |